Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.

整合暴露组和甲基化组,以了解已建立的不同队列中 ADRD 的大脑分子变化。

基本信息

  • 批准号:
    10657846
  • 负责人:
  • 金额:
    $ 98.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-01 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary This is an application for an administrative supplement to enhance the outcome of the parent grant: U01 AG046139 “A Systems Approach to Targeting Innate Immunity in AD”. This Administrative Supplement aims to expand the multiomics profiling in this cohort and enable curation of exposome variables from existing brain bank records. The design of our unique study cohort in the parent award enables us to perform comparative analysis of control (no pathology), PathAg, (Pathologic Aging, amyloid+), AD (tau+, amyloid+) and PSP (progressive supranuclear palsy, tau+) providing a framework to identify therapeutic targets that play a role in the transition to different disease neuropathologic stages of AD. Further, comparisons between two brain regions (TCX=affected and CER=largely spared in AD) and between AD and PSP can help distinguish whether the molecular changes identified are likely a cause or consequence of pathology. We have collected multiomics measures in ~350 study participants, including genetic (WGS), transcriptomic (RNAseq) and epigenomic (ChIP- Seq) data. In collaboration with other consortia members, proteomic, metabolomic and lipidomic measures were/will also be collected. The study cohort in the parent award is focused on non-Hispanic White (NHW) individuals. Through the AMP-AD diversity initiative supplement, we expanded this study to understudied racial/ethnic minority cohorts comprising African American (AA) and Latin American (LA) participants. These efforts have generated complementary genetic, transcriptomic and proteomic measures on >200 diverse individuals. However, complementary DNA methylation data is currently lacking from both the parent (NHW) and the diversity supplement (AA, LA) cohorts. The samples in both cohorts are from the Mayo Clinic brain bank and have undergone in-depth neuropathological examination. A similarly in-depth review of available records to curate data on demographic, lifestyle (education, smoking and alcohol consumption), comorbid diseases, as well as specific neuropathological findings indicative of cerebrovascular disease is currently lacking. We hypothesize that the exposome interacts with the epigenome to drive gene expression changes which may underlie regional, cellular and ethno-racial vulnerabilities to neuropathology and ultimately neurodegenerative disease. The goal of this Supplement is to extract and collect exposome and DNA methylation data respectively for participants in the Mayo Clinic AMP-AD cohorts. Our specific aims are: 1. Identify exposome variables in an established post-mortem cohort of multi-ethnic participants with existing and new (methylome) brain multi-omics data. 2. Discover differentially methylated regions in brain associated with AD/ADRD diagnosis, neuropathology, and exposome phenotypes. 3. Identify impacts of AD, related neuropathologies and exposome phenotypes on the DNA methylation profile of key brain cell types in AD. We expect to identify differentially methylated regions (DMRs) that reveal the molecular mechanisms underlying brain regional and cellular vulnerabilities in AD and their interactions with exposome and race/ethnicity that may drive this.
项目摘要 这是一份行政补助申请,以提高父母补助金的效果:U 01 AG046139“A Systems Approach to Targeting Innate Immunity in AD”。本行政补充文件旨在 扩展该队列中的多组学分析,并从现有的 大脑银行记录我们在家长奖中独特的研究队列的设计使我们能够进行比较 对照(无病理)、PathAg(病理老化,淀粉样蛋白+)、AD(tau+,淀粉样蛋白+)和PSP的分析 (进行性核上性麻痹,tau+)提供了一个框架,以确定在 向AD的不同疾病神经病理学阶段的转变。此外,比较两个大脑区域 (TCX=受影响,CER=在AD中基本上不受影响)以及AD和PSP之间的差异有助于区分 鉴定的分子变化可能是病理的原因或结果。我们收集了多组学 在约350名研究参与者中进行了测量,包括遗传学(WGS)、转录组学(RNAseq)和表观基因组学(ChIP)。 Seq)数据。与其他联盟成员合作,进行蛋白质组学、代谢组学和脂质组学测量 也将被收集。父母奖的研究队列集中在非西班牙裔白色(NHW) 个体通过AMP-AD多样性倡议补充,我们将本研究扩展到了 种族/少数民族队列,包括非洲裔美国人(AA)和拉丁美洲人(LA)参与者。这些 在超过200个不同的基因组中, 个体然而,目前缺乏来自亲本(NHW)的互补DNA甲基化数据。 和多样性补充(AA,LA)队列。两个队列中的样本均来自马约诊所脑库 并接受了深入的神经病理学检查。对现有记录进行类似的深入审查, 收集人口统计学、生活方式(教育、吸烟和饮酒)、共病数据, 以及目前缺乏指示脑血管疾病的特定神经病理学发现。我们 假设该基因组与表观基因组相互作用以驱动基因表达变化, 是区域性、细胞性和民族性神经病理学脆弱性的基础, 疾病本增刊的目的是分别提取和收集染色体组和DNA甲基化数据 对于马约诊所AMP-AD队列的参与者。我们的具体目标是:1.确定在一个 建立了具有现有和新(甲基化组)脑多组学的多种族参与者的尸检队列 数据2.发现与AD/ADRD诊断,神经病理学, 和麻烦的表型。3.确定AD、相关神经病理学和干扰素组表型对 AD中关键脑细胞类型的DNA甲基化图谱。我们希望能找出差异甲基化的 区域(DMR),揭示大脑区域和细胞的分子机制 AD的脆弱性及其与可能导致这种情况的麻烦和种族/民族的相互作用。

项目成果

期刊论文数量(77)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Dense data enables 21st century clinical trials.
A systems-biology clinical trial of a personalized multimodal lifestyle intervention for early Alzheimer's disease.
  • DOI:
    10.1002/trc2.12191
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    McEwen SC;Merrill DA;Bramen J;Porter V;Panos S;Kaiser S;Hodes J;Ganapathi A;Bell L;Bookheimer T;Glatt R;Rapozo M;Ross MK;Price ND;Kelly D;Funk CC;Hood L;Roach JC
  • 通讯作者:
    Roach JC
Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains.
  • DOI:
    10.1186/s13024-016-0137-9
  • 发表时间:
    2016-11-25
  • 期刊:
  • 影响因子:
    15.1
  • 作者:
    Ma L;Allen M;Sakae N;Ertekin-Taner N;Graff-Radford NR;Dickson DW;Younkin SG;Sevlever D
  • 通讯作者:
    Sevlever D
Handgrip Strength Is Related to Hippocampal and Lobar Brain Volumes in a Cohort of Cognitively Impaired Older Adults with Confirmed Amyloid Burden.
  • DOI:
    10.3233/jad-220886
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Meysami, Somayeh;Raji, Cyrus A.;Glatt, Ryan M.;Popa, Emily S.;Ganapathi, Aarthi S.;Bookheimer, Tess;Slyapich, Colby B.;Pierce, Kyron P.;Richards, Casey J.;Lampa, Melanie G.;Gill, Jaya M.;Rapozo, Molly K.;Hodes, John F.;Tongson, Ynez M.;Wong, Claudia L.;Kim, Mihae;Porter, Verna R.;Kaiser, Scott A.;Panos, Stella E.;Dye, Richelin, V;Miller, Karen J.;Bookheimer, Susan Y.;Martin, Neil A.;Kesari, Santosh;Kelly, Daniel F.;Bramen, Jennifer E.;Siddarth, Prabha;Merrill, David A.
  • 通讯作者:
    Merrill, David A.
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
  • DOI:
    10.1111/jnc.13583
  • 发表时间:
    2016-10
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    Golde TE
  • 通讯作者:
    Golde TE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NILUFER ERTEKIN-TANER其他文献

NILUFER ERTEKIN-TANER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NILUFER ERTEKIN-TANER', 18)}}的其他基金

Discovering Centrally Linked Peripheral Molecular Signatures of Alzheimer's Disease
发现阿尔茨海默病的中心连锁外周分子特征
  • 批准号:
    10555727
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10555724
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
  • 批准号:
    10246077
  • 财政年份:
    2020
  • 资助金额:
    $ 98.9万
  • 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
  • 批准号:
    10475289
  • 财政年份:
    2020
  • 资助金额:
    $ 98.9万
  • 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
  • 批准号:
    10251376
  • 财政年份:
    2020
  • 资助金额:
    $ 98.9万
  • 项目类别:
A Systems Approach to Targeting Innate Immunity in AD
针对 AD 中先天免疫的系统方法
  • 批准号:
    10506095
  • 财政年份:
    2020
  • 资助金额:
    $ 98.9万
  • 项目类别:
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD
利用弹性分子网络进行 AD 治疗发现
  • 批准号:
    10404635
  • 财政年份:
    2018
  • 资助金额:
    $ 98.9万
  • 项目类别:
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD
利用弹性分子网络进行 AD 治疗发现
  • 批准号:
    10170201
  • 财政年份:
    2018
  • 资助金额:
    $ 98.9万
  • 项目类别:
Institutional Career Development Core
机构职业发展核心
  • 批准号:
    10632366
  • 财政年份:
    2017
  • 资助金额:
    $ 98.9万
  • 项目类别:
Institutional Career Development Core
机构职业发展核心
  • 批准号:
    10674613
  • 财政年份:
    2017
  • 资助金额:
    $ 98.9万
  • 项目类别:

相似海外基金

A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
  • 批准号:
    10841820
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
  • 批准号:
    10833895
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
  • 批准号:
    10844667
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
  • 批准号:
    10850135
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
  • 批准号:
    10896844
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
  • 批准号:
    10840220
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
  • 批准号:
    10891050
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
  • 批准号:
    10711717
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
  • 批准号:
    10811292
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
Sedentary behavior, physical activity, and 24-hour behavior in pregnancy and offspring health: the Pregnancy 24/7 Offspring Study Administrative Supplement
久坐行为、体力活动和 24 小时行为对怀孕和后代健康的影响:怀孕 24/7 后代研究行政补充
  • 批准号:
    10893074
  • 财政年份:
    2023
  • 资助金额:
    $ 98.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了